The Cigna Group (CI)
Cigna and CVS shares fall as Trump targets ‘middlemen' in sweeping executive order against Big Pharma
The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.
Cigna Q1 Earnings Beat Estimates on Evernorth Health Strength
CI increases adjusted earnings guidance for 2025 to $29.60 per share from the previous estimate of $29.50.
Cigna (CI) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cigna (CI) Q1 Earnings and Revenues Surpass Estimates
Cigna (CI) came out with quarterly earnings of $6.74 per share, beating the Zacks Consensus Estimate of $6.39 per share. This compares to earnings of $6.47 per share a year ago.
Cigna raises full-year profit forecast, latest to beat medical cost estimates
Cigna on Friday raised its full-year earnings forecast and beat estimates for quarterly profit, helped by strong performance in its pharmacy benefit management business and lower-than-expected medical costs in its insurance arm.
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
CI's first-quarter results are likely to have benefited from growing pharmacy revenues and fees.
Curious about Cigna (CI) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Cigna (CI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Earnings Preview: Cigna (CI) Q1 Earnings Expected to Decline
Cigna (CI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cigna: Fewer Protests, More Potential
Cigna's strong growth, favorable valuation, and shareholder policies justify a "buy" rating, outperforming the S&P500 with a 37% return since May 2023. The integration of insurance with pharmacy benefit management, particularly through Evernorth, enhances cost control and customer retention, driving significant revenue growth. Despite rising medical costs and public dissatisfaction with insurers, Cigna's strategic focus on commercial health plans and PBMs mitigates risks and supports future growth.
The Cigna Group: Compelling Exposure To Diversified Healthcare At A Discount Price
Cigna is positioned to benefit from utilization normalization and aims for 10%-14% annual EPS growth by reducing Medicare exposure and improving Commercial business. Despite industry challenges, Cigna achieved 8%-9% YoY EPS growth in 2023-2024, demonstrating strong cost discipline and effective management. The sale of Cigna's Medicare unit and focus on lower-cost biosimilars and streamlined care accessibility are key strategic moves for future growth.
Cigna shuffles executive roles, names Ann Dennison as CFO
Cigna has made a series of upper management changes, which include making CFO Brian Evanko as the healthcare conglomerate's chief operating officer, and promoting his deputy Ann Dennison to the top finance role.
The Cigna Group (CI) Barclays 27th Annual Global Healthcare Conference (Transcript)
The Cigna Group (NYSE:CI ) Barclays 27th Annual Global Healthcare Conference Call March 12, 2025 2:00 PM ET Company Participants Brian Evanko - Chief Financial Officer of Cigna Group, President, Chief Executive Officer of Cigna Healthcare Conference Call Participants Andrew Mok - Barclays Andrew Mok Hi, good afternoon and welcome back to the Barclays Global Healthcare Conference. My name is Andrew Mok, I'm the facilities and managed care analyst here at Barclays.
